Could Hormone-Related Cancers Start Before Birth?
UMass Amherst scientist will investigate role of estrogen-mimicking chemicals
AMHERST, Mass. -- Much attention has been paid to genetics in breast cancer as disease rates rise, but most women have no family history of the disease, suggesting that there is an environmental risk we don’t yet understand, says environmental health scientist Laura Vandenberg in the School of Public Health and Health Sciences at the University of Massachusetts Amherst.
Now she is launching a three-year, $450,000 research program supported by a National Institutes of Environmental Health Sciences (NIEHS) early career award to investigate the possibility that exposure to estrogen or estrogen-like chemicals in the womb may be a factor. “We already know that the major known risk factor in breast cancer is exposure to estrogen, so girls who enter puberty earlier and women who enter menopause later have higher risk,” she says.
Vandenberg’s investigation will focus on an estrogen-mimicking chemical called bisphenol S (BPS), related to bisphenol A (BPA) and now often used in plastics, thermal receipts, food packaging and other products instead of BPA.
“There are hundreds of papers now on BPA and we have reached the point where there is enough evidence to conclude that it mimics estrogen,” she notes. “In order to say a product is BPA-free, manufacturers have begun to use BPS instead. It is almost entirely unstudied, but a few studies suggest it also acts like an estrogen. We need evidence for each chemical to make decisions about them, and studying these compounds also helps us to better understand how hormone-sensitive organs develop and respond to environmental insults.”
“Most studies have focused on estrogen exposure during puberty and adulthood, but a handful of studies suggest exposure to natural or synthetic estrogens in the womb can increase breast cancer risk,” Vandenberg says. “Unfortunately, just a little bit goes a long way here. For example, girl twins have a higher estrogen exposure in utero, as do the fetuses of women who keep taking birth control pills before they realize they are pregnant. It is a tiny amount, but important.”
Such data suggest that mammary tissue as it develops during gestation is not just sensitive, but is being primed in the womb for disease that appears decades later, Vandenberg says, “and we want to know how.” One of the unusual aspects of her study is that she will investigate possible exposure effects in both male and female mammary tissue.
As part of this NIEHS-sponsored research program, Vandenberg has assembled a team of experts with whom she will study, allowing her to take not only tissue- and cell-based approaches to study effects of chemicals on mammary glands, but also to use surgical, endocrine and molecular tools. The team includes R. Thomas Zoeller, an expert in developmental endocrinology and endocrine-disruptors, and D. Joseph Jerry, an expert on the intersection of hormones and genetics, both at UMass Amherst.
Vandenberg will also study with Suzanne Fenton of NIEHS using the mammary gland to examine environmental toxicants, and Susan Nagel of the University of Missouri to examine endocrine disruptor screening methods and chemical mixtures.
Earlier, Vandenberg was one of the first scientists to study the effect of environmental exposure to chemicals, specifically BPA, on male mammary gland development in mice. Male mice do not have nipples, but they do have mammary glands. For the new work, she says, “One of the big questions we’ll investigate is whether male breast cancer is similar to female breast cancer, in particular whether it also can be initiated early in life.”
Another of the techniques they will use includes transplanting mammary glands from exposed animals into unexposed animals and vice versa to explore whether it is the gland or the whole body that must be exposed to an environmental insult. They will use high-throughput screening techniques to detect genetic effects and study mammary tissue as it develops in the embryo and fetus to see if the genes being turned on have different visualized patterns with in situ hybridization, as well.
-
Most popular related searches
Related news
-
Creative Proteomics Cytokine Unveils Disease Cytokine Assays for Disease Diagnosis
Cytokine division belongs to Creative Proteomics, which specializes in providing cytokine research and analysis services for researchers in the pharmaceutical and biotechnology industries, as well as academic institutes and government agencies. Creative Proteomics Cytokine recently announced Disease Cytokine Assays to help researchers obtain higher quality scientific research data. Cytokines, including interleukins, interferons, tumor necrosis factors, and chemokines, can play key pro- and anti-inflammatory...
-
SeqOne Genomics closes €20M series A to accelerate the deployment of its genomic medicine platform
The round, led by Omnes, Merieux Equity Partners, together with the Software Club and existing investors, Elaia and IRDI Capital Investissement, will enable SeqOne Genomics to accelerate its international sales and the development of new collaborative genomic analysis tools to facilitate communications between different disciplines in the medical team, in order to improve patient outcomes in cancer and hereditary disease. The company will intensify investments in the development of its genomic-aware data lake to...
-
Profacgen Helps Accelerate GPCR Study with Various Services
Profacgen, a global provider of drug screening and profiling services that offers a comprehensive panel of services designed to speed and simplify drug discovery research, now offers professional high-throughput GPCR screening services for identification of potential GPCR-targeting drugs. G protein-coupled receptors (GPCRs) are also known as seven-transmembrane domain receptors. They are present only in eukaryotes. Because of their extensive involvement in cellular signal transduction, GPCRs have emerged as...
-
Phase III trial with Nubeqa (darolutamide) in combination with docetaxel and androgen deprivation therapy meets primary endpoint of significantly increasing overall survival in patients with metastatic hormone-sensitive prostate cancer
ARASENS trial demonstrates an increase in overall survival evaluating darolutamide in combination with docetaxel and androgen deprivation therapy (ADT) compared to docetaxel and ADT, a standard of care in metastatic hormone-sensitive prostate cancer (mHSPC) / Bayer plans to present these pivotal data at a forthcoming scientific congress and to discuss them with health authorities / ARASENS is part of broad development program for darolutamide which includes another ongoing Phase III trial in mHSPC, ARANOTE,...
-
Creative Proteomics Launches Oncology Multi-omics Platform to Promote Basic Oncology Research
Using its mature multi-omics technology platform, Creative Proteomics has been devoted to providing high-quality, personalized oncology multi-omics services and reliable data support to worldwide clients for years. With the continuous aging of human society, the improvement of industrialization, and the deterioration of the quality of living environment, the incidence of cancer is getting higher and higher. Elucidating the mechanisms of tumorigenesis is utterly dire and a crucial research topic. The use of...
Customer comments
No comments were found for Could Hormone-Related Cancers Start Before Birth?. Be the first to comment!